Reflexiones sobre las directrices de actividad física en España

Monthly newsletter providing updates of interest to the Boston University School of Medicine community

Multiteide Project: Multiparametric characterization of the activity of Teide-Pico Viejo volcanic system

European Geosciences Union General Assembly (2017. Viena)Teide-Pico Viejo complex stands for one of the major natural volcanic hazards in the Canary Islands, due to the expected types of eruptions in the area and the high number of inhabitants in Tenerife Island. Therefore, it is necessary to have a volcanic alert system able to afford a precise assessment of the current state of the complex. For this purpose, the knowledge of the expected signals at each volcanic activity level is required. Moreover, the external effects that can affect the measurements shall be distinguished, external influences as the atmosphere are qualitatively known but have not been quantified yetCentro Geofísico de Canarias, Instituto Geográfico Nacional, EspañaObservatorio Geofísico Central, Instituto Geográfico Nacional, EspañaInstituto Geológico y Minero de España, EspañaLaboratoire GéoSciences Réunion, Institut de Physique du Globe de Paris, Centre National de la Recherche Scientifique, EspañaPeer reviewe

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

Introduction The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in cognitive function domains, to analyze subgroups by the low-density lipoprotein cholesterol (LDL-C) achieved, and differences between alirocumab and evolocumab. Methods This has a multicenter, quasi-experimental design carried out in 12 Spanish hospitals from May 2020 to February 2023. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Results Among 158 patients followed for a median of 99 weeks, 52% were taking evolocumab and 48% alirocumab; the mean change from baseline in MoCA score at follow-up was + 0.28 [95% CI (− 0.17 to 0.73; p = 0.216)]. There were no significant differences in the secondary endpoints—the visuospatial/executive domain + 0.04 (p = 0.651), naming domain − 0.01 (p = 0.671), attention/memory domain + 0.01 (p = 0.945); language domain − 0.10 (p = 0.145), abstraction domain + 0.03 (p = 0.624), and orientation domain − 0.05 (p = 0.224)—but for delayed recall memory the mean change was statistically significant (improvement) + 0.44 (p = 0.001). Neither were there any differences in the three stratified subgroups according to lowest attained LDL-C level—0–54 mg/dL, 55–69 mg/dL and ≥ 70 mg/dL; p = 0.454—or between alirocumab and evolocumab arms. Conclusion We did not find effect of monoclonal antibody PCSK9i on neurocognitive function over 24 months of treatment, either in global MoCA score or different cognitive domains. An improvement in delayed recall memory was shown. The study showed no differences in the cognitive function between the prespecified subgroups, even among patients who achieved very low levels of LDL-C. There were no differences between alirocumab and evolocumab. Registration ClinicalTtrials.gov Identifier number NCT04319081Open Access funding provided thanks to the CRUE-CSIC agreement with Springer NatureS

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

IMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes